Oseltamivir Dosing Guidelines
Adult and Adolescent Dosing (≥13 years)
For treatment of influenza, adults and adolescents should receive 75 mg orally twice daily for 5 days, initiated within 48 hours of symptom onset. 1, 2
- Prophylaxis: 75 mg once daily for 10 days following exposure, or up to 6 weeks during community outbreaks 1, 3
- Taking oseltamivir with food significantly reduces nausea and vomiting (the most common adverse effects, occurring in ~10% of patients) without affecting antiviral efficacy 1, 2
- Complete the full 5-day course even if symptoms improve earlier—early discontinuation increases resistance risk 1
Pediatric Dosing (Children ≥12 months)
Weight-based dosing is required for children 1–12 years, administered twice daily for 5 days: 1, 2, 3
| Body Weight | Treatment Dose | Prophylaxis Dose | Suspension Volume (6 mg/mL) |
|---|---|---|---|
| ≤15 kg (≤33 lb) | 30 mg twice daily | 30 mg once daily | 5 mL |
| >15–23 kg (>33–51 lb) | 45 mg twice daily | 45 mg once daily | 7.5 mL |
| >23–40 kg (>51–88 lb) | 60 mg twice daily | 60 mg once daily | 10 mL |
| >40 kg (>88 lb) | 75 mg twice daily | 75 mg once daily | 12.5 mL |
- Prophylaxis duration is 10 days post-exposure or up to 6 weeks during community outbreaks 1, 3
- Use the oral suspension (6 mg/mL) with a calibrated oral syringe—never household spoons 1, 4
Infant Dosing (<12 months)
Term infants require age-based mg/kg dosing, NOT the weight-category table used for older children: 1, 2
- 0–8 months: 3 mg/kg per dose twice daily for 5 days 1, 3
- 9–11 months: 3.5 mg/kg per dose twice daily for 5 days 1, 3
- Prophylaxis (3–11 months): 3 mg/kg once daily for 10 days 1
- Prophylaxis (<3 months): NOT recommended unless the situation is judged critical due to limited safety data 1, 2
- FDA approval for treatment begins at 2 weeks of age 1, 4
Critical Measurement Requirements for Infants
- Calculate the exact mg/kg dose and measure the corresponding volume of 6 mg/mL suspension using a 3 mL or 5 mL calibrated oral syringe 1, 4
- The syringe supplied with commercial oseltamivir is unsuitable for infant volumes 1
Preterm Infant Dosing (Post-menstrual Age-Based)
Preterm infants require substantially lower doses than term infants due to immature renal function—using term-infant dosing causes toxic drug concentrations: 1, 2, 4
| Post-menstrual Age (PMA)* | Dose (twice daily for 5 days) |
|---|---|
| <38 weeks | 1.0 mg/kg |
| 38–40 weeks | 1.5 mg/kg |
| >40 weeks | 3.0 mg/kg |
*PMA = gestational age + chronological age 1
- For extremely preterm infants (<28 weeks PMA), consult a pediatric infectious disease specialist before initiating therapy 1, 4
Renal Impairment Dose Adjustments
Dose reduction is mandatory when creatinine clearance falls below 60 mL/min—failure to adjust leads to drug accumulation and toxicity: 1, 2, 4
Treatment Regimen (5 days)
| Creatinine Clearance | Adjusted Dose |
|---|---|
| >30–60 mL/min | 30 mg twice daily |
| 10–30 mL/min | 75 mg once daily OR 30 mg once daily |
| ESRD on hemodialysis | 30 mg immediately, then 30 mg after each dialysis session (max 5 days) |
| ESRD on CAPD | Single 30 mg dose immediately |
| ESRD not on dialysis | NOT recommended |
Prophylaxis Regimen
| Creatinine Clearance | Adjusted Dose |
|---|---|
| >30–60 mL/min | 30 mg once daily |
| 10–30 mL/min | 30 mg every other day OR 75 mg every other day (5 total doses over 10 days) |
| ESRD on hemodialysis | 30 mg immediately, then 30 mg after alternate dialysis cycles |
| ESRD on CAPD | 30 mg immediately, then 30 mg once weekly |
Elderly Patients (≥65 years)
No dose reduction is required based on age alone—standard adult dosing (75 mg twice daily) applies. 1, 2, 4
- However, renal function declines with aging, so creatinine clearance must be assessed and dose adjusted accordingly when CrCl <60 mL/min 1, 2
Special Populations
Pregnancy and Breastfeeding
- Dosing is identical to non-pregnant adults: 75 mg twice daily for 5 days 2, 4
- Breastfeeding is NOT a contraindication to oseltamivir use 2, 4
Immunocompromised Patients
- Standard dosing applies 4
- Treatment should be initiated regardless of time elapsed since symptom onset 4
High-Risk Groups Requiring Treatment Even After 48 Hours
- Hospitalized patients with severe or progressive influenza 4
- Children <2 years 4
- Adults ≥65 years 4
- Pregnant women 4
- Individuals with chronic cardiac or respiratory disease 4
- Immunocompromised patients 4
Formulations and Administration
- Capsules: 30 mg, 45 mg, 75 mg
- Oral suspension: 6 mg/mL after reconstitution
If commercial suspension is unavailable: 1, 4
- Pharmacies can compound a 6 mg/mL suspension according to package insert instructions
- Capsules can be opened and mixed with sweetened liquid (e.g., simple syrup)
Critical Timing Considerations
Initiate treatment within 48 hours of symptom onset for maximal benefit—earlier initiation (≤36 hours) yields even faster symptom resolution. 1, 2, 4
- Treatment reduces illness duration by 1–1.5 days compared to placebo 1, 5
- Treatment decreases secondary complications (bronchitis, pneumonia, sinusitis) and subsequent antibiotic use 1, 5
- Prophylaxis should be started within 48 hours of exposure to infected individuals 2
Common Pitfalls to Avoid
- Do NOT use weight-category dosing (≤15 kg = 30 mg) for infants <12 months—they require mg/kg dosing 1, 4
- Do NOT apply term-infant dosing to preterm infants—PMA-based dosing is required to avoid toxicity 1, 2, 4
- Do NOT round doses inappropriately—calculate the exact mg/kg dose and measure precisely 1, 4
- Do NOT use household spoons—always use a calibrated oral dosing device 1, 4
- Do NOT stop therapy early even if symptoms improve—complete the full 5-day course to prevent resistance 1, 4
- Do NOT forget to assess renal function in elderly patients—age alone does not require dose reduction, but impaired renal function does 1, 2
Adverse Effects and Management
- Nausea and vomiting occur in approximately 10–15% of patients and are mild, transient, and typically resolve within 1–2 days 1, 2, 4
- Taking oseltamivir with food markedly reduces gastrointestinal side effects 1, 2, 4
- Only ~1% of patients discontinue therapy due to gastrointestinal effects 1, 4